Holen Sie sich die Stockscreener-App
0.3301
4.36%
0.0138
Handel nachbörslich:
.33
-0.000100
-0.03%
Schlusskurs vom Vortag:
$0.3163
Offen:
$0.3185
24-Stunden-Volumen:
2.06M
Relative Volume:
2.13
Marktkapitalisierung:
$5.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.07M
KGV:
-0.0571
EPS:
-5.78
Netto-Cashflow:
$-7.34M
1W Leistung:
+34.19%
1M Leistung:
-52.54%
6M Leistung:
-68.87%
1J Leistung:
-68.26%
1-Tages-Spanne:
$0.3002
$0.3305
1-Wochen-Bereich:
$0.2715
$0.532
52-Wochen-Spanne:
$0.22
$3.00
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Firmenname
Adial Pharmaceuticals Inc
Sektor
Branche
Telefon
434-422-9800
Adresse
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Vergleichen Sie ADIL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
0.3301 | 5.18M | 0 | -6.07M | -7.34M | -5.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2018-10-30 | Eingeleitet | Maxim Group | Buy |
| 2018-10-11 | Eingeleitet | Dawson James | Buy |
Adial Pharmaceuticals Inc Aktie (ADIL) Neueste Nachrichten
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering - GlobeNewswire
Adial Pharmaceuticals (ADIL) Announces Public Offering to Raise $3.6M - GuruFocus
Adial Pharmaceuticals prices $3.6 million public offering - Investing.com
Adial Pharmaceuticals (ADIL) Sets Pricing for Stock and Warrants Offering | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering | ADIL Stock News - GuruFocus
Adial Pharmaceuticals prices $3.6 million public offering By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals Secures $3.6M Financing: New Shares at $0.32 Plus Warrant Package - Stock Titan
Adial Pharmaceuticals Announces New Annual Meeting Date By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals Announces New Annual Meeting Date - Investing.com
Adial Pharmaceuticals Reschedules 2025 Annual Meeting Date - TipRanks
Adial Pharmaceuticals Inc (ADIL) Stock: From Low to High in 52 Weeks - investchronicle.com
Adial Pharmaceuticals (ADIL) Advances Toward Phase 3 with FDA Meeting Preparation | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting - GlobeNewswire
Market Update: Adial Pharmaceuticals Inc (ADIL) Sees Negative Movement, Closing at 0.35 - DWinneX
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 63.0% in May - Defense World
ADIL Stock on the Rise: A Promising Investment - investchronicle.com
Adial Pharmaceuticals advances Phase 3 trial design for alcohol disorder drug By Investing.com - Investing.com South Africa
EXCLUSIVE: Intelligent Bio Solutions Expands US Forensic Market Presence, Seeks FDA Clearance For Fingerprint Drug Testing - AOL.com
Adial Pharmaceuticals advances Phase 3 trial design for alcohol disorder drug - Investing.com
Adial Pharmaceuticals (ADIL) Advances Phase 3 Trial Plans for AD04 | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04 - The Manila Times
Revolutionary AI-Powered Phase 3 Trial: How Adial Plans to Transform Alcohol Addiction Treatment - Stock Titan
EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial - Yahoo Finance
ADIL: A.G.P./Alliance Global Partners Appointed as Sole Placemen - GuruFocus
ADIL: A.G.P./Alliance Global Partners Appointed as Sole Placement Agent | ADIL Stock News - GuruFocus
Adial Pharmaceuticals (ADIL) Files to Sell Over 6 Million Shares - GuruFocus
Adial Pharmaceuticals Faces Nasdaq Non-Compliance Notice - TipRanks
Adial Pharmaceuticals (ADIL) Files to Sell Over 6 Million Shares | ADIL Stock News - GuruFocus
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
ADIL Q2 EPS Increased by Brookline Capital Management - Defense World
Adial Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Adial Pharmaceuticals sets new proposal deadline By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals sets new proposal deadline - Investing.com
Adial Pharmaceuticals (ADIL) Reports Q1 2025 Results | ADIL Stoc - GuruFocus
Adial Pharmaceuticals Reports First Quarter 2025 Financial Resul - GuruFocus
Adial Pharmaceuticals (ADIL) Reports Q1 2025 Results | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Q1 2025 Financial Results and Business Update - TradingView
Adial Pharmaceuticals Advances AUD Drug to Phase 3, Cuts Losses by 66% in Q1 2025 Earnings - Stock Titan
ADIAL PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Adial Pharmaceuticals (ADIL) Receives Milestone Payment for Asth - GuruFocus
Adial Pharmaceuticals (ADIL) Receives Milestone Payment for Asthma Drug Development | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study - The Manila Times
Adial Pharmaceuticals (ADIL) Projected to Post Quarterly Earnings on Tuesday - Defense World
FDA to Review Adial’s Phase 3 Trial Plan for AUD Treatment - Investing.com Nigeria
FDA Has Granted Request for End of Phase 2 Meeting to Discuss Alcohol Use Disorder Treatment, AD04 - Psychiatric Times
FDA to Review Adial’s Phase 3 Trial Plan for AUD Treatment By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Granted End Of Phase 2 Meeting From FDA - marketscreener.com
EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program - AOL.com
Adial Pharmaceuticals (ADIL) Receives FDA Green Light for Phase 3 Meeting | ADIL Stock News - GuruFocus
Finanzdaten der Adial Pharmaceuticals Inc-Aktie (ADIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):